IGM Biosciences (IGMS) plans to slash its workforce by 73% to preserve cash and assess strategic alternatives to maximize value for shareholders.
Developments of the imvotamab and IGM-2644 autoimmunity pipeline programs are being halted, the company said Thursday in a statement.
"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success," IGM Chief Executive Officer Mary Beth Harler said in the statement.
"Concurrent with discontinuation of the imvotamab program, IGM-2644 is also being terminated due to strategic considerations," Harler said.
The company said it had unaudited cash and investments of $183.8 million as of Dec. 31.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。